United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery

United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery

Summary

Our new report, “United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery” provides key market data on the United States Diabetes Care Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

- Market size and company share data for Diabetes Care Devices market categories – Glucose Monitoring and Insulin Delivery.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the two market categories.
- Global corporate-level profiles of key companies operating within the United States Diabetes Care Devicesmarket.
- Key players covered include LifeScan, Inc., Medtronic, Inc., Bayer HealthCare AG, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the United States Diabetes Care Devices competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize. SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 Diabetes Care Devices In United States
3.1 Diabetes Care Devices, Market Segmentation
3.2 Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018
3.3 Diabetes Care Devices Market, United States, Revenue Mix ($m), 2011
3.4 Diabetes Care Devices Market, United States, Category Contribution (%), 2011
3.5 Diabetes Care Devices, United States, Company Share (2010-2011)
4 Glucose Monitoring In United States
4.1 Glucose Monitoring, Market Segmentation
4.2 Glucose Monitoring Market, United States, Revenue Mix ($m), 2011
4.3 Glucose Monitoring Market, United States, Segment Contribution (%), 2011
4.4 Glucose Monitoring Overall Revenue, (2004-2018)
4.4.1 Blood Glucose Meters, Revenue (2004-2018)
4.5 Glucose Monitoring Overall Volume (2004-2018)
4.5.1 Blood Glucose Meters, Volume (2004-2018)
4.6 Glucose Monitoring Average Price (2004-2018)
4.7 Glucose Monitoring Distribution Share (2010-2011)
4.8 Glucose Monitoring, United States, Company Share (2010-2011)
5 Insulin Delivery In United States
5.1 Insulin Delivery Market, United States, Revenue Mix ($m), 2011
5.2 Insulin Delivery Market, United States, Segment Contribution (%), 2011
5.3 Insulin Delivery Overall Revenue, (2004-2018)
5.3.1 Insulin Pens, Revenue (2004-2018)
5.3.2 Insulin Pumps, Revenue (2004-2018)
5.4 Insulin Delivery Overall Volume (2004-2018)
5.4.1 Insulin Pens, Volume (2004-2018)
5.4.2 Insulin Pumps, Volume (2004-2018)
5.5 Insulin Delivery Average Price (2004-2018)
5.6 Insulin Delivery Distribution Share (2010-2011)
5.7 Insulin Delivery, United States, Company Share (2010-2011)
6 Overview of Key Companies in United States Diabetes Care Devices Market
6.1 LifeScan, Inc.
6.1.1 Company Overview
6.1.2 Share in the United States Diabetes Care Devices Market
6.2 Medtronic, Inc.
6.2.1 Company Overview
6.2.2 Share in the United States Diabetes Care Devices Market
6.3 Bayer HealthCare AG
6.3.1 Company Overview
6.3.2 Share in the United States Diabetes Care Devices Market
6.4 F. Hoffmann-La Roche Ltd.
6.4.1 Company Overview
6.4.2 Share in the United States Diabetes Care Devices Market
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Share in the United States Diabetes Care Devices Market
6.6 Becton, Dickinson and Company
6.6.1 Company Overview
6.6.2 Share in the United States Diabetes Care Devices Market
6.7 Eli Lilly and Company
6.7.1 Company Overview
6.8 Animas Corporation
6.8.1 Company Overview
6.9 Novo Nordisk A/S
6.9.1 Company Overview
6.10 Sanofi
6.10.1 Company Overview
6.11 Insulet Corporation
6.11.1 Company Overview
6.12 ARKRAY, Inc.
6.12.1 Company Overview
6.13 B. Braun Melsungen AG
6.13.1 Company Overview
7 Diabetes Care Devices Market Pipeline Products
8 Financial Deals Landscape
8.1 Acquisition
8.1.1 LifeScan Acquires Calibra Medical
8.1.2 Arriva Medical Acquires AmMed Direct For $23 Million
8.1.3 ActiveCare To Acquire 4G Biometrics, Healthcare Technology Company
8.1.4 DexCom Completes Acquisition Of SweetSpot Diabetes Care For Up To $8.5 Million
8.1.5 Arriva Medical Acquires Direct Diabetic Source
8.1.6 Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For $36 Million
8.1.7 Alere Acquires Arriva Medical From Palm Beach Capital For $83 Million
8.2 Partnerships
8.2.1 Nextgen Healthcare Enters Into Technology Integration Agreement With Nipro Diagnostics
8.2.2 Alere Enters Into Co-Development Agreement With AT&T
8.2.3 Telcare Enters Into Licensing Agreement With Diabetech For GlucoDynamix-ADMS
8.2.4 Tethys Bioscience Enters Into Technology Integration Agreement With Lose It
8.2.5 Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson
8.2.6 Juvenile Diabetes Research Foundation Enters Into Co-Development Agreement With Helmsley Charitable Trust And Medtronic
8.2.7 Tandem Diabetes Enters Into Licensing Agreement With DexCom
8.2.8 Roche Diagnostics Enters Into Distribution Agreement With DexCom
8.2.9 Roche Diagnostics Enters Into Research And Development Agreement With DexCom
8.2.10 Pal Health Enters Into Distribution Agreement With Surefit For Xtremityone
9 Recent Developments
9.1 Strategy And Business Planning
9.1.1 Aug 28, 2012: Medtronic Opens Shanghai Innovation Center
9.1.2 Aug 09, 2012: Takeda Establishes Development Center In China
9.1.3 Jun 26, 2012: Roche To Shut New Jersey Site, Eliminate 1,000 Jobs
9.1.4 May 22, 2012: Greatbatch To Establish New Global Headquarters
9.1.5 Mar 21, 2012: HealthMed To Expand Portfolio Of Products Beyond Organ Transplantation
9.1.6 Feb 27, 2012: Greatbatch Announces Engagement To Advance Medical Device Strategy
9.1.7 Jan 26, 2012: Nipro Diagnostics Purchases New Building, Expands Fort Lauderdale Operations
9.1.8 Jan 19, 2012: BD And Mercy/ROi Collaborate To Improve Quality Of Care And Reduce Costs
9.1.9 Oct 19, 2011: Abbott To Separate Into Two Leading Companies In Diversified Medical Products And Research-Based Pharmaceuticals
9.1.10 Oct 13, 2011: Unisense Establishes US Headquarter
9.2 Research And Development
9.2.1 Jul 17, 2012: Greatbatch To Establish R&D Centre In Singapore
9.2.2 Mar 21, 2012: Index Ventures Launches New €150m Life Sciences Fund With Investments From GSK And Janssen
9.2.3 Jan 09, 2012: Bayer HealthCare To Share Lab Space With Start-Up Companies
9.3 Legal and Regulatory
9.3.1 Jun 29, 2012: Sucampo Pharma Provides Update On Anticipated Arbitration Decision
9.3.2 May 30, 2012: Sucampo Announces Change In Date Of Anticipated Arbitration Decision In Dispute With Takeda
9.3.3 Apr 17, 2012: Sanmina-SCI Suzhou, China Facility Receives ISO 13485 Certification For Medical Devices
9.3.4 Mar 30, 2012: Medtronic Reaches Settlement Of Shareholder Class Action
9.3.5 Dec 23, 2011: Glancy Binkow Announces Class Action Lawsuit Against Hospira
9.3.6 Dec 13, 2011: Medtronic Reaches Settlement With US Department of Justice
9.3.7 Nov 22, 2011: Izard Nobel Announces Class Action Lawsuit Against Hospira
9.4 Government and Public Interest
9.4.1 Jun 28, 2012: American Diabetes Association Applauds US Supreme Court Decision To Uphold Affordable Care Act
9.4.2 Jun 15, 2012: American Diabetes Association Applauds Passage Of Connecticut House Bill 5348
9.4.3 Jun 15, 2012: American Diabetes Association Applauds Federal Funding For Diabetes Research And Prevention
9.4.4 Jun 15, 2012: OSA Is Associated With Diabetic Peripheral Neuropathy: Study
9.4.5 May 23, 2012: Beta Cell Imaging Could Help Spot Diabetes Earlier: Vanderbilt University
9.4.6 Mar 13, 2012: Researchers Identify Optimal Threshold For HbA1c Test For Prediabetes
9.4.7 Mar 01, 2012: Diabetes Research Institute Develops Revolutionary Oxygen-Generating Biomaterial To Enhance Islet Survival
9.4.8 Feb 13, 2012: Blood From Periodontal Disease Can Be Used To Screen For Diabetes: NYU Study
9.4.9 Jan 20, 2012: Researchers At Brown University Develops Biochip To Measures Glucose In Saliva
9.4.10 Jan 11, 2012: American Diabetes Association Applauds Revised US State Department Policy
9.4.11 Jan 03, 2012: Maternal Liver Grafts More Tolerable For Children With Rare Disease: UCSF
9.4.12 Oct 14, 2011: MannKind To Present At 18th Annual Newsmakers In BioTech Industry Conference
9.4.13 Sep 29, 2011: Research At UC Reveals Hormone Action That Could Lead To Treatments For Type 2 Diabetes
9.4.14 Sep 14, 2011: Medtronic Pledges Action In Advance of United Nations High Level Meeting On Noncommunicable Diseases
9.5 Product News
9.5.1 Oct 28, 2011: ARKRAY's GLUCOCARD Vital And 01 Blood Glucose Meters Are Listed On DoD Uniform Formulary
9.5.2 Jun 29, 2010: Medtronic Announces STAR 3 Trial Results Confirming MiniMed Paradigm REAL-Time System Achieves Better Glucose Control Than Daily Insulin Injections In Diabetic Patients
9.5.3 Jun 25, 2010: Medtronic Begins Enrollment In ASPIRE Pivotal Study Of MiniMed Paradigm x54 System
9.5.4 Mar 17, 2010: Medtronic Announces FDA Approval Of MiniMed Paradigm REAL-Time Revel System
9.5.5 Aug 05, 2009: Continuous Glucose Monitoring Benefits Even Well-Controlled Type 1 Diabetics
9.5.6 Jul 10, 2009: Medtronic Announces Voluntary Recall Of Paradigm Specific Lots Of Quick-Set Infusion Sets
9.5.7 Jun 07, 2009: Medtronic Presents REAL Trend Study Results Of MiniMed Paradigm REAL-Time System At 69th Annual Scientific Sessions Of The ADA
9.5.8 May 05, 2009: Bayer HealthCare Releases CONTOUR Meters In Two Bold New Colors, The Midnight Blue And Orange Burst
10 Appendix
10.1 Definitions of Markets Covered in the Report
10.1.1 Diabetes Care Devices
10.2 Research Methodology
10.3 Secondary Research
10.4 Primary Research
10.5 Models
10.6 Forecasts
10.7 Expert Panels
10.8 Consulting
10.9 Currency Conversion
10.10 Contact Us
10.11 Disclaimer

1.1 List of Tables
Table 1: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018
Table 2: Diabetes Care Devices Market, United States, Category Contribution (%), 2011
Table 3: Diabetes Care Devices, United States, Cross-Segment Analysis, 2004-2018
Table 4: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Table 5: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Table 6: Diabetes Care Devices, United States, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 7: Glucose Monitoring Market, United States, Segment Contribution (%), 2011
Table 8: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 9: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 10: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 11: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 12: Glucose Monitoring, United States, Volume (Units) by Segment, Historic, 2004-2011
Table 13: Glucose Monitoring, United States, Volume (Units) by Segment, Forecast, 2011-2018
Table 14: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011
Table 15: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018
Table 16: Glucose Monitoring, United States, Average Price ($), Historic, 2004-2011
Table 17: Glucose Monitoring, United States, Average Price ($), Forecast, 2011-2018
Table 18: Glucose Monitoring, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 19: Glucose Monitoring, United States, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 20: Insulin Delivery Market, United States, Segment Contribution (%), 2011
Table 21: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 22: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 23: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 24: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 25: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 26: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 27: Insulin Delivery, United States, Volume (Units) by Segment, Historic, 2004-2011
Table 28: Insulin Delivery, United States, Volume (Units) by Segment, Forecast, 2011-2018
Table 29: Insulin Pens, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011
Table 30: Insulin Pens, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018
Table 31: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011
Table 32: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018
Table 33: Insulin Delivery, United States, Average Price ($), Historic, 2004-2011
Table 34: Insulin Delivery, United States, Average Price ($), Forecast, 2011-2018
Table 35: Insulin Delivery, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 36: Insulin Delivery, United States, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 37: Diabetes Care Devices Market Pipeline Products
Table 38: LifeScan Acquires Calibra Medical
Table 39: Arriva Medical Acquires AmMed Direct For $23 Million
Table 40: ActiveCare To Acquire 4G Biometrics, Healthcare Technology Company
Table 41: DexCom Completes Acquisition Of SweetSpot Diabetes Care For Up To $8.5 Million
Table 42: Arriva Medical Acquires Direct Diabetic Source
Table 43: Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For $36 Million
Table 44: Alere Acquires Arriva Medical From Palm Beach Capital For $83 Million
Table 45: Nextgen Healthcare Enters Into Technology Integration Agreement With Nipro Diagnostics
Table 46: Alere Enters Into Co-Development Agreement With AT&T
Table 47: Telcare Enters Into Licensing Agreement With Diabetech For GlucoDynamix-ADMS
Table 48: Tethys Bioscience Enters Into Technology Integration Agreement With Lose It
Table 49: Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson
Table 50: Juvenile Diabetes Research Foundation Enters Into Co-Development Agreement With Helmsley Charitable Trust And Medtronic
Table 51: Tandem Diabetes Enters Into Licensing Agreement With DexCom
Table 52: Roche Diagnostics Enters Into Distribution Agreement With DexCom
Table 53: Roche Diagnostics Enters Into Research And Development Agreement With DexCom
Table 54: Pal Health Enters Into Distribution Agreement With Surefit For Xtremityone

1.2 List of Figures
Figure 1: Diabetes Care Devices, Market Segmentation
Figure 2: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018
Figure 3: Diabetes Care Devices Market, United States, Revenue Mix ($m), 2011
Figure 4: Diabetes Care Devices Market, United States, Category Contribution (%), 2011
Figure 5: Diabetes Care Devices, United States, Cross-Segment Analysis, 2004-2018
Figure 6: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Figure 7: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Figure 8: Diabetes Care Devices, United States, Company Share (%), 2011
Figure 9: Glucose Monitoring, Market Segmentation
Figure 10: Glucose Monitoring Market, United States, Revenue Mix ($m), 2011
Figure 11: Glucose Monitoring Market, United States, Segment Contribution (%), 2011
Figure 12: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 13: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 14: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 15: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 16: Glucose Monitoring, United States, Volume (Units) by Segment, Historic, 2004-2011
Figure 17: Glucose Monitoring, United States, Volume (Units) by Segment, Forecast, 2011-2018
Figure 18: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011
Figure 19: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018
Figure 20: Glucose Monitoring, United States, Company Share (%), 2011
Figure 21: Insulin Delivery, Market Segmentation
Figure 22: Insulin Delivery Market, United States, Revenue Mix ($m), 2011
Figure 23: Insulin Delivery Market, United States, Segment Contribution (%), 2011
Figure 24: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 25: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 26: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 27: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 28: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 29: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 30: Insulin Delivery, United States, Volume (Units) by Segment, Historic, 2004-2011
Figure 31: Insulin Delivery, United States, Volume (Units) by Segment, Forecast, 2011-2018
Figure 32: Insulin Pens, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011
Figure 33: Insulin Pens, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018
Figure 34: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011
Figure 35: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018
Figure 36: Insulin Delivery, United States, Company Share (%), 2011
Figure 37: LifeScan, Inc., Company Share (%),United States Diabetes Care Devices Market, 2011
Figure 38: Medtronic, Inc., Company Share (%),United States Diabetes Care Devices Market, 2011
Figure 39: Bayer HealthCare AG, Company Share (%),United States Diabetes Care Devices Market, 2011
Figure 40: F. Hoffmann-La Roche Ltd., Company Share (%),United States Diabetes Care Devices Market, 2011
Figure 41: Abbott Laboratories, Company Share (%),United States Diabetes Care Devices Market, 2011
Figure 42: Becton, Dickinson and Company, Company Share (%),United States Diabetes Care Devices Market, 2011

LifeScan, Inc.
Medtronic, Inc.
Bayer HealthCare AG
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Becton, Dickinson and Company
Eli Lilly and Company
Animas Corporation
Novo Nordisk A/S
Sanofi
Insulet Corporation
ARKRAY, Inc.
B. Braun Melsungen AG